Pelacarsen Stumbles in Phase III Cardiovascular Outcomes Trial
NVS sits 27% above its 52-week low of $121.57.
Summary
Novartis announced that its Phase III Lp(a)HORIZON trial for pelacarsen failed to meet its primary endpoint of reducing cardiovascular events, despite achieving lower Lp(a) levels.
Key Events · Product Development and Regulatory · NVS
-
Phase III Trial Misses Primary Endpoint
Pelacarsen failed to reduce the composite of cardiovascular death, non-fatal MI, non-fatal stroke, and urgent coronary revascularization versus placebo in the Lp(a)HORIZON trial.
-
Lp(a) Lowering Did Not Translate to Benefit
Lower Lp(a) levels were achieved, but this did not reduce cardiovascular risk in the overall study population of 8,323 patients with elevated Lp(a) and established CVD.
-
Pipeline Setback
Pelacarsen was a key late-stage asset targeting elevated Lp(a), an inherited risk factor affecting ~20% of people worldwide with no approved targeted treatment.
-
Data Presentation Planned
Full Lp(a)HORIZON trial data will be presented at an upcoming medical congress.
Analysis · NVS · Life Sciences
A pivotal cardiovascular outcomes study in over 8,000 patients has failed to show that pelacarsen reduces major adverse cardiovascular events, despite lowering Lp(a) levels. This is a major setback for a drug positioned as a potential first-in-class treatment for elevated Lp(a), a condition affecting roughly one in five people worldwide. The failure removes a significant pipeline opportunity and raises questions about the Lp(a) hypothesis itself, though Novartis notes the data may inform future approaches. The stock is likely to react negatively as investors reassess the cardiovascular franchise.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.8% of the 1864 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NVS was trading at $154.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $297.7B. The 52-week trading range was $121.57 to $170.46. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.